[HTML] nature.com

[HTML][HTML] The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer

VYF Su, KY Yang, TY Huang, CC Hsu, YM Chen… - Scientific reports, 2020 - nature.com
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
被引用次数：25 相关文章

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer

VYF Su, KY Yang, TY Huang, CC Hsu… - Scientific …, 2020 - scholar.nycu.edu.tw
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
[HTML] nih.gov

[HTML][HTML] The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer

VYF Su, KY Yang, TY Huang, CC Hsu, YM Chen… - Scientific …, 2020 - ncbi.nlm.nih.gov
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.

VYF Su, KY Yang, TY Huang, CC Hsu… - Scientific …, 2020 - search.ebscohost.com
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.

VY Su, KY Yang, TY Huang, CC Hsu, YM Chen… - Scientific …, 2020 - europepmc.org
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer

VYF Su, KY Yang, TY Huang, CC Hsu… - Scientific …, 2020 - pubmed.ncbi.nlm.nih.gov
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …